Helicobacter pylori: Factors Related to Therapeutic Resistance and Current Approaches
Keywords:
antibacterial resistance; bacterial disease; chronic gastritis; dual therapy for H pylori
Abstract
Introduction: Helicobacter pylori (H. pylori), a Gram-negative bacterium, poses a global health threat linked to chronic gastritis, gastric ulcers, and adenocarcinoma. This literature review addresses H. pylori challenges, emphasizing therapeutic resistance and modern treatment strategies.
Downloads
How to Cite
References
L Thomsen, J Gavin, Tasman- Jones, C (1990) Relation of Helicobacter pylori to the human gastric mucosa in chronic gastritis of the antrum. 31(11), 1230-1236.
Thamirys Teixeira, Iure De Souza, Roberta Rocha (2017) Helicobacter pylori: infecção, diagnóstico laboratorial e tratamento. 6(12), 481.
Azucena Arévalo, William Otero, Alba Trespalacios (2019) Helicobacter pylori: resistencia múltiple en pacientes de Bogotá, Colombia. 39(1), 125-134.
James Hooi, Wan Lai, Wee Ng, Michael Suen, Fox Underwood, Divine Tanyingoh, Peter Malfertheiner, David Graham, Vincent Wong, Justin Wu, Francis Chan, Joseph Sung, Gilaad Kaplan, Siew Ng (2017) Global Prevalence of Helicobacter pylori Infection: Systematic Review and Meta-Analysis. 153(2), 420-429.
Luiz Coelho, James Marinho, Robert Genta, Laercio Ribeiro, Maria Passos, Schlioma Zaterka, Paulo Assumpção, Alfredo Barbosa, Ricardo Barbuti, Lucia Braga, Helenice Breyer, Aloisio Carvalhaes, Décio Chinzon, Marcelo Cury, Gerson Domingues, Jorge Jorge, Ismael Maguilnik, Frederico Marinho, Joaquim Moraes-Filho, José Parente, Celso Paula-E-Silva, José Pedrazzoli-Júnior, Ana Ramos, Heinrich Seidler, José Spinelli, José Zir (2018) IVTH BRAZILIAN CONSENSUS CONFERENCE ON HELICOBACTER PYLORI INFECTION. 55(2), 97-121.
Mei Zhang (2015) High antibiotic resistance rate: A difficult issue forHelicobacter pylorieradication treatment. 21(48), 13432.
(2018) Pan American Health Organization (PAHO) Regional Office of the World Health Organization (WHO). 582-582.
David Graham (2020) Transitioning of Helicobacter pylori Therapy from Trial and Error to Antimicrobial Stewardship. 9(10), 671.
Ki Huh, Hyewon Chung, Yu Kim, Seunghwan Lee, Siddharth Bhatia, Yohei Takanami, Ryou Nakaya, Kyung‐sang Yu (2022) Evaluation of safety and pharmacokinetics of bismuth‐containing quadruple therapy with either vonoprazan or lansoprazole for Helicobacter pylori eradication. 88(1), 138-144.
Hanxin Bi, Xingxing Chen, Yuxin Chen, Xin Zhao, Shasha Wang, Jiehong Wang, Ting Lyu, Shuang Han, Tao Lin, Mingquan Li, Donghong Yuan, Junye Liu, Yongquan Shi (2022) Efficacy and safety of high-dose esomeprazole-amoxicillin dual therapy for Helicobacter pylori rescue treatment: a multicenter, prospective, randomized, controlled trial. 135(14), 1707-1715.
Chih-An Shih, Chang-Bih Shie, Wei-Chen Tai, Seng-Kee Chuah, Hsi-Chang Lee, Null- Hsu (2023) Update on the second-line treatment of Helicobacter pylori infection: a narrative review. 16, 175628482311-92750.
Nicola Jones, Sibylle Koletzko, Karen Goodman, Patrick Bontems, Samy Cadranel, Thomas Casswall, Steve Czinn, Benjamin Gold, Jeannette Guarner, Yoram Elitsur, Matjaž Homan, Nicolas Kalach, Michal Kori, Armando Madrazo, Francis Megraud, Alexandra Papadopoulou, Marion Rowland (2017) Joint ESPGHAN/NASPGHAN Guidelines for the Management of Helicobacter pylori in Children and Adolescents (Update 2016). 64(6), 991-1003.
L Lu, Y Wang, J Ye, Y Han, G Lou, Y Li, H Yan, Q Du (2023) Quadruple therapy with vonoprazan 20 mg daily as a first-line treatment for Helicobacter pylori infection: A single-center, open-label, noninferiority, randomized controlled trial. 28(1), 12940.
M Koroglu, M Ayvaz, M Ozturk (2022) The Efficacy of Bismuth Quadruple Therapy, Sequential Therapy, and Hybrid Therapy as a First-Line Regimen for Helicobacter pylori Infection Compared with Standard Triple Therapy. 25(9), 1535-1541.
Cristian Parra-Sepúlveda, José Merino, Katia Sáez-Carrillo, Carlos González, Apolinaria García-Cancino (2019) ANTIBIOTIC RESISTANCE SURVEILLANCE OF HELICOBACTER PYLORI AT THE BIOBÍO REGION (CHILE) IN A DECADE. 56(4), 361-366.
William Chey, Francis Mégraud, Loren Laine, Luis López, Barbara Hunt, Colin Howden (2022) Vonoprazan Triple and Dual Therapy for Helicobacter pylori Infection in the United States and Europe: Randomized Clinical Trial. 163(3), 608-619.
Yi Hu, Xin Xu, Xiao-Shun Liu, Cong He, Yao-Bin Ouyang, Nian-Shuang Li, Chuan Xie, Chao Peng, Zhen-Hua Zhu, Yong Xie, Xu Shu, Yin Zhu, David Graham, Nong-Hua Lu (2023) Fourteen-day vonoprazan and low- or high-dose amoxicillin dual therapy for eradicating Helicobacter pylori infection: A prospective, open-labeled, randomized non-inferiority clinical study. 13, 1049908.
Yoon Choi, Yong Lee, Jung Kim, Jin Kim, Jeong Moon, Yun Lim, Gwang Baik, Byoung Son, Hang Lee, Kyoung Kim, Nayoung Kim, Kwang Ko, Hye-Kyung Jung, Ki-Nam Shim, Hoon Chun, Byung-Wook Kim, Hyuk Lee, Jie-Hyun Kim, Hyunsoo Chung, Sang Kim, Jae Jang (2022) Triple Therapy-Based on Tegoprazan, a New Potassium-Competitive Acid Blocker, for First-Line Treatment of Helicobacter pylori Infection: A Randomized, Double-Blind, Phase III, Clinical Trial. 16(4), 535-546.
Ping‐ Hsu, Feng‐woei Tsay, John Kao, Nan‐jing Peng, Yan‐hua Chen, Sheng‐yeh Tang, Chao‐hung Kuo, Sung‐shuo Kao, Huay‐min Wang, I‐ting Wu, Chang‐bih Shie, Seng‐kee Chuah, Deng‐chyang Wu (2021) Tetracycline‐levofloxacin versus amoxicillin‐levofloxacin quadruple therapies in the second‐line treatment of Helicobacter pylori infection. 26(5), 12840.
Xueping Huang, Baihe Wu, Qiuzhao Chen, Yushan Chen, Xinhua Ji, Xiang Zhou, Biao Suo, Zhihui Lin, Xiaoling Zheng (2023) Antibiotic resistance profile of Helicobacter pylori to 14 antibiotics: a multicenter study in Fujian, China. 11, e15611.
Ngoc Dang, Thi Ha, Si-Tuan Nguyen, Nguyen Le, Thi Nguyen, Thanh Nguyen, Thi Pham, Van Tran (2020) High rates of clarithromycin and levofloxacin resistance of Helicobacter pylori in patients with chronic gastritis in the south east area of Vietnam. 22, 620-624.
Trung Tran, Anh Nguyen, Duc Quach, Dao Thi-Hong Pham, Nga Cao, Uyen Thi-Hong Nguyen, An Nguyen-Thanh Dang, Minh Tran, Loc Quach, Khiem Tran, Nhan Le, Viet Ung, Minh Ngoc-Quoc Vo, Danh Nguyen, Kha Ngo, Trung Tran, Vy Nguyen (2022) Emergence of amoxicillin resistance and identification of novel mutations of the pbp1A gene in Helicobacter pylori in Vietnam. 22(1), 41.
Laisheng Luo, Yingjie Ji, Lou Yu, Yu Huang, Xiao Liang, David Graham, Hong Lu (2020) 14-Day High-Dose Amoxicillin- and Metronidazole-Containing Triple Therapy With or Without Bismuth as First-Line Helicobacter pylori Treatment. 65(12), 3639-3646.
Macedo Silva, V, Lima Capela, T Freitas, M, Boal Carvalho, P Magalhães, J Cotter, J (2023) A "new" option in Helicobacter pylori eradication: High-dose amoxicillin dual therapy outperforms bismuth quadruple therapy in a high dual resistance setting. 28(3), 12962.
Seung Seo, Hyun Lim, Chang Bang, Young Yang, Gwang Baik, Sang Lee, Hyun Jang, Sea Kae, Jinseob Kim, Hak Kim, Woon Shin (2022) Bismuth-Based Quadruple Therapy versus Metronidazole-Intensified Triple Therapy as a First-Line Treatment for Clarithromycin-Resistant Helicobacter pylori Infection: A Multicenter Randomized Controlled Trial. 16(5), 697-705.
Sarita Ratana‐amornpin, Likasith Sanglutong, Thanee Eiamsitrakoon, Sith Siramolpiwat, David Graham, Varocha Mahachai (2023) Pilot studies of vonoprazan‐containing Helicobacter pylori eradication therapy suggest Thailand may be more similar to the US than Japan. 28(6), 13019.
Tiago Benigno, Howard Ribeiro Junior, Orleâncio Azevedo, Ronald Pinheiro, Roberta Oliveira, Felipe Maciel, Edson Oliveira, Dulciene Queiroz, Lucia Braga (2022) Clarithromycin-resistant H. pylori primary strains and virulence genotypes in the Northeastern region of Brazil. 64, 47.
Yu‐zhen Wang, Jie Chen, Shi‐qin Pei, Chen Wang, Gang Han, Lian‐di Kan, Liu‐cheng Li (2023) Treatment strategies and pharmacist‐led medication management for Helicobacter pylori infection. 84(2), 326-336.
Claudio Alba, Ana Blanco, Teresa Alarcón (2017) Antibiotic resistance in Helicobacter pylori. 30(5), 489-497.
Aya Ahmed, Gehan Balata, Hany Elsadek, Ahmed Amin (2020) Review: Treatment of Helicobacter pylori infection. 0(0), 11-23.
Sho Suzuki, Chika Kusano, Toshiki Horii, Ryoji Ichijima, Hisatomo Ikehara (2021) The Ideal Helicobacter pylori Treatment for the Present and the Future. 103(1), 62-68.
Sung Ko, Yeon‐ji Kim, Woo Chung, Seung Lee (2019) Bismuth supplements as the first‐line regimen for Helicobacter pylori eradication therapy: Systemic review and meta‐analysis. 24(2), 12565.
Lan Li, Weihua Zhou, Hongzhang Li, Chaohui Yu, Tianlian Yan, Ningmin Yang, You-Ming Li (2021) Antibiotic Resistance of Helicobacter pylori Isolated from Patients after Partial Gastrectomy: A Retrospective Study. 32(12), 996-1002.
Francis Megraud, Samuel Coenen, Ann Versporten, Manfred Kist, Manuel Lopez-Brea, Alexander Hirschl, Leif Andersen, Herman Goossens, Youri Glupczynski (2013) Helicobacter pylori resistance to antibiotics in Europe and its relationship to antibiotic consumption. 62(1), 34-42.
Shamshul Ansari, Yoshio Yamaoka (2022) Helicobacter pylori Infection, Its Laboratory Diagnosis, and Antimicrobial Resistance: a Perspective of Clinical Relevance. 35(3), 25821.
J Caetano (2023) IV Consenso Brasileiro sobre Infecção pelo Helicobacter pylori.
Published
2024-06-07
Issue
Section
License
Copyright (c) 2024 Authors and Global Journals Private Limited
This work is licensed under a Creative Commons Attribution 4.0 International License.